Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28595299 | 0.97 | MAP4K4 (0.48) | MAP4K4OPRM1TNFSLC6A4SLC6A3 | |
| SCHEMBL15821832 | 0.95 | MAP4K4 (0.47) | MAP4K4OPRM1TNFSLC6A4SLC6A3 | |
| SCHEMBL350982 | 0.93 | OPRM1 (0.42) | MAP4K4OPRM1TNF | |
| SCHEMBL29574467 | 0.93 | OPRM1 (0.42) | MAP4K4OPRM1TNF | |
| SCHEMBL15129658 | 0.85 | OPRM1 (0.38) | MAP4K4OPRM1TNFSLC6A4SLC6A3 | |
| SCHEMBL5309575 | 0.85 | OPRM1 (0.38) | MAP4K4OPRM1TNFMAP3K12 | |
| SCHEMBL15129340 | 0.84 | PDE4A (0.41) | MAP4K4OPRM1TNFSLC6A4SLC6A3 | |
| SCHEMBL31014508 | 0.81 | OPRM1 (0.33) | MAP4K4OPRM1TNFNPC1RAB9A | |
| SCHEMBL30485528 | 0.79 | MAP4K4 (0.42) | MAP4K4OPRM1MEN1NPC1ALDH1A1 | |
| SCHEMBL20489483 | 0.79 | MAP4K4 (0.45) | MAP4K4OPRM1MEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2023-10-26 | — | — | US | disclosed |
| EP-3372601-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-02-24 | — | — | US | disclosed |
| WO-2021104186-A1 | NOVEL SALTS OF INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | InventisBio Co., Ltd. (CN) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021102618-A1 | NOVEL SALTS OF INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | InventisBio Co., Ltd. (CN) | 2021-06-03 | — | — | WO | disclosed |
| US-10980807-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | INVENTISBIO LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20200046697-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2020-02-13 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| WO-2013116182-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | WO | disclosed |
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| EP-2619197-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120295896-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295896-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295896-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2012040139-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | MAP4K4 3728/4885OPRM1 1965/4885TNF 1183/4885 |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTB4R2, LTC4S | MAP4K4 3244/4885OPRM1 4011/4885TNF 925/4885 |
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | MAP4K4 3224/4885OPRM1 1289/4885TNF 507/4885 |
| US-20120295896-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | MAP4K4 3673/4885OPRM1 2049/4885TNF 751/4885 |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | MAP4K4 678/4885OPRM1 3847/4885TNF 4236/4885 |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | MAP4K4 3728/4885OPRM1 1965/4885TNF 1183/4885 |
| US-20200046697-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | MAP4K4 3728/4885OPRM1 1965/4885TNF 1183/4885 |
| US-10980807-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | IDO1, IDO2, INMT | MAP4K4 3728/4885OPRM1 1965/4885TNF 1183/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | MAP4K4 895/4885OPRM1 3883/4885TNF 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.